Compounds > sabiporide
Page last updated: 2024-11-11

sabiporide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

sabiporide: a NHE-1 inhibitor and a cardioprotective agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9868115
CHEMBL ID2105423
SCHEMBL ID1286662
MeSH IDM0452989

Synonyms (19)

Synonym
n-(diaminomethylidene)-4-[4-(1h-pyrrole-2-carbonyl)piperazin-1-yl]-3-(trifluoromethyl)benzamide
unii-u52apa00x7
biib 722
n-carbamimidoyl-4-(4-(1h-pyrrol-2-ylcarbonyl)piperazin-1-yl)-3-(trifluoromethyl)benzamide
sabiporide hcl
sabiporide [inn]
biib722
324758-66-9
biib 722cl
u52apa00x7 ,
biib-722
sabiporide
CHEMBL2105423
bdbm50396462
4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine
SCHEMBL1286662
261505-80-0
Q27290695
DTXSID00870321

Research Excerpts

Treatment

Treatment with sabiporide significantly attenuated the increase in PAP by 38% and PVR by 67%, as well as significantly improved cardiac output by 51%. SabipOride treatment also improved mixed venous blood oxygen saturation.

ExcerptReferenceRelevance
"Sabiporide treatment also improved mixed venous blood oxygen saturation (55% in sabiporide group vs."( Sabiporide improves cardiovascular function, decreases the inflammatory response and reduces mortality in acute metabolic acidosis in pigs.
Abraham, WM; Kraut, JA; Wu, D, 2013)		2.55
"Treatment with sabiporide significantly attenuated the increase in PAP by 38% and PVR by 67%, as well as significantly improved cardiac output by 51%."( Sabiporide improves cardiovascular function, decreases the inflammatory response and reduces mortality in acute metabolic acidosis in pigs.
Abraham, WM; Kraut, JA; Wu, D, 2013)		2.17

Pharmacokinetics

ExcerptReferenceRelevance
" In this study, we characterized the pharmacodynamic properties of new guanidine NHE1 inhibitors (cariporide, sabiporide, KR-32511, KR-32570, and KR-33028) to analyze their myocardial protective effects."( Pharmacodynamic characteristics and cardioprotective effects of new NHE1 inhibitors.
Han, W; Jung, YS; Kim, J; Kim, KH; Kim, MY; Lee, BH; Lee, MG; Namkung, W; Yi, KY; Yoo, SE, 2007)		0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium/hydrogen exchanger 1Homo sapiens (human)IC50 (µMol)0.02800.00500.56013.5000AID701661
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (40)

Processvia Protein(s)Taxonomy
monoatomic ion transportSodium/hydrogen exchanger 1Homo sapiens (human)
intracellular sodium ion homeostasisSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of pHSodium/hydrogen exchanger 1Homo sapiens (human)
response to acidic pHSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophySodium/hydrogen exchanger 1Homo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingSodium/hydrogen exchanger 1Homo sapiens (human)
cell migrationSodium/hydrogen exchanger 1Homo sapiens (human)
maintenance of cell polaritySodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of cell growthSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to insulin stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilitySodium/hydrogen exchanger 1Homo sapiens (human)
response to muscle stretchSodium/hydrogen exchanger 1Homo sapiens (human)
sodium ion export across plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of apoptotic processSodium/hydrogen exchanger 1Homo sapiens (human)
negative regulation of apoptotic processSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of action potentialSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISodium/hydrogen exchanger 1Homo sapiens (human)
stem cell differentiationSodium/hydrogen exchanger 1Homo sapiens (human)
protein complex oligomerizationSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of intracellular pHSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of stress fiber assemblySodium/hydrogen exchanger 1Homo sapiens (human)
regulation of focal adhesion assemblySodium/hydrogen exchanger 1Homo sapiens (human)
cardiac muscle cell differentiationSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to coldSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to antibioticSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to electrical stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to mechanical stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to organic cyclic compoundSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to hypoxiaSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to acidic pHSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to epinephrine stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cardiac muscle cell contractionSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of cardiac muscle cell membrane potentialSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of the force of heart contraction by cardiac conductionSodium/hydrogen exchanger 1Homo sapiens (human)
sodium ion import across plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of the force of heart contractionSodium/hydrogen exchanger 1Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of calcium:sodium antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
potassium ion transmembrane transportSodium/hydrogen exchanger 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
calmodulin bindingSodium/hydrogen exchanger 1Homo sapiens (human)
phospholipid bindingSodium/hydrogen exchanger 1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingSodium/hydrogen exchanger 1Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
protein phosphatase 2B bindingSodium/hydrogen exchanger 1Homo sapiens (human)
protein-macromolecule adaptor activitySodium/hydrogen exchanger 1Homo sapiens (human)
identical protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
calcium-dependent protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
molecular adaptor activitySodium/hydrogen exchanger 1Homo sapiens (human)
sodium:proton antiporter activity involved in regulation of cardiac muscle cell membrane potentialSodium/hydrogen exchanger 1Homo sapiens (human)
potassium:proton antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
cytoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
mitochondrionSodium/hydrogen exchanger 1Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
focal adhesionSodium/hydrogen exchanger 1Homo sapiens (human)
cell surfaceSodium/hydrogen exchanger 1Homo sapiens (human)
intercalated discSodium/hydrogen exchanger 1Homo sapiens (human)
membraneSodium/hydrogen exchanger 1Homo sapiens (human)
basolateral plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
apical plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
lamellipodiumSodium/hydrogen exchanger 1Homo sapiens (human)
T-tubuleSodium/hydrogen exchanger 1Homo sapiens (human)
membrane raftSodium/hydrogen exchanger 1Homo sapiens (human)
perinuclear region of cytoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
extracellular exosomeSodium/hydrogen exchanger 1Homo sapiens (human)
cation-transporting ATPase complexSodium/hydrogen exchanger 1Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID701655Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID701661Inhibition of NHE1 in human HT-29 cells assessed as intracellular pH change after 30 mins2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID701665Clearance in jugular and femoral vein precannulated Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis relative to hepatic blood flow2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID701658Inhibition of CYP2C19 in human liver microsomes using 7-ethoxy-3-cyanocoumarin as substrate after 45 mins by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID701663Volume of distribution at steady state in jugular and femoral vein precannulated Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID701664Mean resident time in jugular and femoral vein precannulated Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID701660Inhibition of NHE1 in human platelet rich plasma assessed as reduction of propionate medium induced platelet swelling measured every 6 secs for 5 mins2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID701662Oral bioavailability in jugular and femoral vein precannulated Sprague-Dawley rat plasma at 5 mg/kg by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (46.67)29.6817
2010's8 (53.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		2.45202-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.110isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
sucrose
Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.		2.0510glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.0310mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
thiazoles
[no description available]		2.02101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
evans blue
Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.		2.0510organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		2.0210amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.0210glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
colforsin
Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.		2.0310acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.0210organic bromide saltcolorimetric reagent;
dye
cariporide
cariporide: a selective sodium-hydrogen exchange subtype 1 inhibitor; structure in first source		2.4620
sodium bicarbonate
Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.		2.5120one-carbon compound;
organic sodium salt		antacid;
food anticaking agent
eniporide
eniporide: inhibits NHE-1 isoform; structure in first source		2.0710
zoniporide
zoniporide: inhibits sodium-hydrogen exchanger isoform-1 (NHE-1)		2.0710
phosphocreatine
Phosphocreatine: An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996). phosphagen : Any of a group of guanidine or amidine phosphates that function as storage depots for high-energy phosphate in muscle with the purpose of regenerating ATP from ADP during muscular contraction.. N-phosphocreatine : A phosphoamino acid consisting of creatine having a phospho group attached at the primary nitrogen of the guanidino group.		2.0210phosphagen;
phosphoamino acid		human metabolite;
mouse metabolite
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.0810aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
(5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine
(5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine: KR-32570 possesses potent cardioprotective effects in perfused rat hearts, and its effects may be mediated by inhibition of NHE-1, preservation of high-energy phosphates, and inhibition of lipid peroxidation		2.0310
kr-33028
N-(4-cyano-benzo(b)thiophene-2-carbonyl)guanidine: a cardioprotective agent for preventing ischemia-reperfusion injury; structure in first source		2.0310
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.0710cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Cardiovascular Stroke
[description not available]		02.7530
Injury, Myocardial Reperfusion
[description not available]		02.4820
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		07.7530
Arrhythmia
[description not available]		07.0810
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		02.0810
Blood Poisoning
[description not available]		02.110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.1550
MODS
[description not available]		02.110
Ascites
Accumulation or retention of free fluid within the peritoneal cavity.		02.110
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		02.110
Multiple Organ Failure
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.		02.110
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		07.110
Suffocation
[description not available]		02.4920
Asystole
[description not available]		02.110
Asphyxia
A pathological condition caused by lack of oxygen, manifested in impending or actual cessation of life.		07.4920
Heart Arrest
Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.		02.110
Metabolic Acidosis
[description not available]		07.520
Acidosis
A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.		07.520
Cerebral Infarction, Middle Cerebral Artery
[description not available]		02.0510
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.		02.0510
Hibernation, Myocardial
[description not available]		02.0810
Injury, Ischemia-Reperfusion
[description not available]		02.4420
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		02.4420
Hypovolemic
[description not available]		02.0810
Heritable Pulmonary Arterial Hypertension
[description not available]		02.0810
Bleeding
[description not available]		02.0810
Pulmonary Hypertension
[description not available]		02.0810
Innate Inflammatory Response
[description not available]		02.0810
Hemorrhage
Bleeding or escape of blood from a vessel.		02.0810
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.		02.0810
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0810
Hypovolemia
An abnormally low volume of blood circulating through the body. It may result in hypovolemic shock (see SHOCK).		02.0810
Familial Primary Pulmonary Hypertension
Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.		02.0810
Ventricular Dysfunction
A condition in which HEART VENTRICLES exhibit impaired function.		02.0210
Cardiac Failure
[description not available]		02.4320
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		02.4320
Anterior Cerebral Circulation Infarction
[description not available]		02.0210
Cerebral Ischemia
[description not available]		02.0210
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		07.0210
Brain Infarction
Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.		02.0210
Cardiac Remodeling, Ventricular
[description not available]		02.0310
Endomyocardial Fibrosis
A condition characterized by the thickening of the ventricular ENDOCARDIUM and subendocardium (MYOCARDIUM), seen mostly in children and young adults in the TROPICAL CLIMATE. The fibrous tissue extends from the apex toward and often involves the HEART VALVES causing restrictive blood flow into the respective ventricles (CARDIOMYOPATHY, RESTRICTIVE).		02.0310